Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination
Authors:
Open Access
- 9 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1447807
Abstract
Background: Threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) are common essential kinases that collaborate in activating the spindle assembly checkpoint (SAC) at the kinetochore, ensuring appropriate chromosome alignment and segregation prior to mitotic exit. Targeting of either TTK or PLK1 has been clinically evaluated in cancer patients; however, dual inhibitors have not yet been pursued. Here we present the in vitro and in vivo characterization of a first in class, dual TTK/PLK1 inhibitor (BAL0891).Methods: Mechanism of action studies utilized biochemical kinase and proteomics-based target-engagement assays. Cellular end-point assays included immunoblot- and flow cytometry-based cell cycle analyses and SAC integrity evaluation using immunoprecipitation and immunofluorescence approaches. Anticancer activity was assessed in vitro using cell growth assays and efficacy was evaluated, alone and in combination with paclitaxel and carboplatin, using mouse models of triple negative breast cancer (TNBC).Results: BAL0891 elicits a prolonged effect on TTK, with a transient activity on PLK1. This unique profile potentiates SAC disruption, forcing tumor cells to aberrantly exit mitosis with faster kinetics than observed with a TTK-specific inhibitor. Broad anti-proliferative activity was demonstrated across solid tumor cell lines in vitro. Moreover, intermittent intravenous single-agent BAL0891 treatment of the MDA-MB-231 mouse model of TNBC induced profound tumor regressions associated with prolonged TTK and transient PLK1 in-tumor target occupancy. Furthermore, differential tumor responses across a panel of thirteen TNBC patient-derived xenograft models indicated profound anticancer activity in a subset (~40%). Using a flexible dosing approach, pathologically confirmed cures were observed in combination with paclitaxel, whereas synergy with carboplatin was schedule dependent.Conclusions: Dual TTK/PLK1 inhibition represents a novel approach for the treatment of human cancer, including TNBC patients, with a potential for potent anticancer activity and a favorable therapeutic index. Moreover, combination approaches may provide an avenue to expand responsive patient populations.Keywords
Funding Information
- Basilea Pharmaceutica
This publication has 61 references indexed in Scilit:
- Seize the engine: Emerging cell cycle targets in breast cancerClinical and Translational Medicine, 2024
- First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumoursEuropean Journal of Cancer, 2022
- Future prospects for mitosis-targeted antitumor therapiesBiochemical Pharmacology, 2021
- Regulating a key mitotic regulator, polo‐like kinase 1 (PLK1)Cytoskeleton, 2018
- Integrated network analysis and machine learning approach for the identification of key genes of triple‐negative breast cancerJournal of Cellular Biochemistry, 2018
- Genomic and Functional Approaches to Understanding Cancer AneuploidyCancer Cell, 2018
- Plk1 and Mps1 Cooperatively Regulate the Spindle Assembly Checkpoint in Human CellsCell Reports, 2015
- Phosphoregulation of Spc105 by Mps1 and PP1 Regulates Bub1 Localization to KinetochoresCurrent Biology, 2012
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1Developmental Cell, 2008